Previous close | 95.69 |
Open | 95.50 |
Bid | 96.81 x 900 |
Ask | 97.59 x 800 |
Day's range | 95.01 - 97.47 |
52-week range | 75.25 - 129.29 |
Volume | |
Avg. volume | 808,842 |
Market cap | 9.374B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 62.61 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 29 Dec 1995 |
1y target est | N/A |
Neurocrine Biosciences ( NASDAQ:NBIX ) Full Year 2022 Results Key Financial Results Revenue: US$1.49b (up 31% from FY...
It hasn't been the best quarter for Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) shareholders, since the share price...
Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?